Lectura farmacodinámica de la sensibilidad antibiótica a Streptococcus pneumoniae

Medicina Clinica

Volumn 113, Issue 3, 1999, Pages 103-108

  Soriano, Francisco ^a,b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Fundacion Jimenez Diaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; PENICILLIN V; QUINOLONE DERIVATIVE; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ADULT; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL MENINGITIS; CHILD; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; INFUSION; LOBAR PNEUMONIA; MICROBIOLOGICAL EXAMINATION; ORAL DRUG ADMINISTRATION; PENICILLIN RESISTANCE; PROSPECTIVE STUDY; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; DRUG EFFICACY; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS;

4-QUINOLONES; ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CHILD; HUMANS; INFUSIONS, PARENTERAL; MACROLIDES; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLINS; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; TETRACYCLINE RESISTANCE;

EID: 0033606421     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Kislak JW, Razavi LMB, Daly AK, Finland M. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci 1965; 250: 261-268.
2. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967; 2; 264-265.
3. Hansman D, Glasgow HN, Sturt J, Devitt HL, Douglas R. Increased resistance to penicillin of pneumococcus isolated from man. N Engl J Med 1971; 284: 175-177.
4. Hansman D. Antibiotic sensitivity pattern of pneumococci relatively insensitive to penicillin and cephalosporin antibiotics. Med J Aust 1975; 2: 740-742.
5. Appelbaum PC, Bhamjee A, Scragg JN, Hallett AF, Bowen AJ, Cooper RC. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977; 2: 995-997.
6. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA Freiman I et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299: 735-740.
7. Casal J. Antimicrobial susceptibility of Streptococcus pneumoniae: serotype distribution of penicillin-resistant strains in Spain. Antimicrob Agents Chemother 1982; 22: 222-225.
8. Fenoll A, Martín-Bourgon C, Muñoz R, Vicioso D, Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991; 13: 56-60.
9. Liñares J, Pallarés R, Alonso T, Pérez JL, Ayats J, Gudiol F et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge hospital, Barcelona, Spain (1979-1990). Clin Infect Dis 1992; 15: 99-105.
10. García de Lomas J, y Grupo Español para la Vigilancia de Patógenos Respiratorios. Situación epidemiológica actual y resistencia de los patógenos respiratorios en España. Med Clin (Barc) 1998; 110 (Supl 1): 44-51.
11. Friedland IR, McCracken OH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377-382.
12. Pallarés R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333; 474-480.
13. Klugman KP. The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 1996; 38 (Supl A): 133-140.
14. Soriano F. Dosificación ideal y pauta de administración de los antibióticos betalactámicos orales en el tratamiento de la infección neumocócica. Enferm Infecc Microbiol Clin 1993; 11 (Supl 1): 44-50.
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Eight informational supplement. Villanova, PA, EE.UU.: M100-S8 NCCLS, 1998.
16. Sanford JP, Gilbert DN, Sande MA. Guía de terapéutica antimicrobiana. Dallas: Antimicrobial Therapy Inc., 1996.
17. a ed.). Nueva York: Churchill Livingstone, 1995; 492-528.
18. Mastrandrea V, Ripa S, La Rosa F, Tarsi R. Human intravenous and intramuscular pharmacokinetics of amoxicillin. Int J Pharmacol Res 1984; 4: 209-212.
19. Grüneberg RN. The Alexander project: using in vitro susceptibility data for choosing empirical therapy in LRT. J Antimicrobial Chemother 1996; 39 (Supl A): 155-170.
20. a ed.). Barcelona: Masson, S.A., 1997.
21. Bremón® i.v. Claritromicina. Ficha técnica. Barcelona: Laboratorios PENSA, 1997.
22. Ellner PD, Neu HC. The inhibitory quotient. JAMA 1981; 246: 1.575-1.578.
23. Soriano F. Optimal dosage of β-lactam antibiotics. Time over the MIC and inoculum effect. J Antimicrob Chemother 1992; 30: 566-569.
24. Soriano F, Ponte C, Santamaría M, Jiménez-Arriero M. Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escherichia coli. J Antimicrob Chemother 1990; 25: 621-627.
25. Soriano F, García-Corbeira P, Ponte C, Fernández-Roblas R, Gadea I. Correlation of pharmacodynamic parameters of five β-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother 1996; 40: 2.686-2.690.
26. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32: 289-297.
27. Vogelman B, Gudmundsson S, Leggett J, Turnige J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
28. Drusano GL, Goldstein FW. Relevance of the Alexander project: pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (Supl A): 141-154.
29. Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother 1994; 38: 2.730-2.737.
30. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother 1996; 38 (Supl A): 117-132.
31. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171-196.
32. Viladrich PF, Gudiol F, Liñares J, Rufi G, Ariza J, Pallarés R. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med 1988; 84: 839-846.
33. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity and treatment. Clin Infect Dis 1992; 14: 801-807.
34. Sloas MM, Barrett FF, Chesney PJ, English BK, Hill BC, Tenover FC et al. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1992; 11: 662-666.
35. Friedland IR, Shelton S, Paris M, Rinderknecht S, Ehrett S, Krisher KA et al. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1993; 12: 196-200.
36. Bradley IS, Connor ID. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J 1991; 10: 871-873.
37. Viladrich PF, Cabellos C, Pallares R, Tubau F, Martínez-Lacasa J, Liñares J et al. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40: 218-220.
38. Marchant CD, Shurin PA, Johnson CE, Murdell-Panek D, Feinstein JC, Fulton D et al. A randomized controlled trial of amoxicillin plus clavulanate compared with cefaclor for treatment of acute otitis media. J Pediatr 1986; 109: 891-896.
39. Dagan R, Abramson O, Leibovitz E, Lang R, Goshen S, Greenberg D et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J 1996; 15: 980-985.
40. Gehanno P, Lenoir G, Berche P. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother 1995; 39: 271-272.
41. Friedland IR. Cefixime therapy for otitis media. Pediatr Infect Dis J 1993; 12: 544-545.
42. Ottolini MG, Ascher DP, Cieslak TJ, Modica-Lucero S. Pneumococcal bacteremia during oral treatment with cefixime for otitis media. Pediatr Infect Dis J 1991; 10: 467-468.
43. Cenjor C, Ponte C, Parra A, Nieto E, García-Calvo G, Giménez MJ et al. In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media. Antimicrob Agents Chemother 1998; 42: 1.361-1.364.
44. Sánchez C, Armengol R, Lite J, Mir I, Garau J. Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet 1992; 339: 988.
45. Moreno S, García-Leoni ME, Cercenado E, Díaz MD, Bernaldo de Quirós JC, Bouza E. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995; 20: 1.195-1.200.
46. Reid R Jr, Bradley JS, Hindler J. Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatr Infect Dis J 1995; 14: 1.104-1.105.
47. Bohte R, Van't Wout JW, Lobatto S, Blussé van Oud Alblas A, Boekhout M, Nauta EH et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995; 14: 182-187.
48. Pérez-Trallero E, García-Arenzana JM, Jiménez JA, Peris A. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1990; 9: 905-906.
49. Lindsay G, Scorer HJN, Carnegie CMD. Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: a randomized, double-blind trial. J Antimicrob Chemother 1992; 30: 89-100.
50. Gordon JJ, Kauffman CA. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med 1990; 89: 383-384.
51. Davies BI, Maesen FPV, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol 1986; 5: 226-231.
52. Gisby J, Wightman BL, Beale AS. Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice. Antimicrob Agents Chemother 1992; 35: 831-836.
53. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992; 339: 405-408.
54. Jackson MA, Shelton S, Nelson JD, McCracken GH. Relatively penicillin-resistant pneumococcal infections in pediatric patients. Pediatr Infect Dis J 1984; 3: 129-132.
55. Moreillon P, Markiewicz Z, Nachman S, Tomasz A. Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms. Antimicrob Agents Chemother 1990; 34: 33-39.
56. Turner GC. Tetracycline-resistant pneumococci in a general hospital. Lancet 1963; 2: 1.292-1.295.
57. Bizzozero OJ, Andriole VT. Tetracycline-resistant pneumococcal infection. Arch Intern Med 1969; 123: 388-393.
58. Schwartz RH, Khan WN, Akran S. Penicillin and trimethoprim-sulphamethoxazoleresistant pneumococci isolated from blood cultures of three infants in metropolitan Washington, DC: a harbinger of serious failure problems? Pediatr Infect Dis J 1991; 10: 782-783.
59. Moore EP, Williams EW. Hospital transmission of multiply antibiotic-resistant Streptococcus pneumoniae. J Infect 1988; 16: 199-200.
60. Citron KM, May JR. Rifamycin antibiotics in chronic purulent bronchitis. Lancet 1969; 2: 982-983.
61. Viladrich PF, Gudiol F, Liñares J, Pallarés R, Sabate I, Rufi G et al. Evaluation of vancomycin in the therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35: 2.467-2.472.
62. Buzón LM, Guerrero A, Romero J, Santamaría JM, Bouza E. Penicillin-resistant Streptococcus pneumoniae meningitis successfully treated with vancomycin. Eur J Clin Microbiol 1984; 3: 442-443.